Compass Pathways Announces $150 Million Underwritten Offering to Advance Mental Health Treatments
Key Insights
Compass Pathways has announced an underwritten offering expected to generate gross proceeds of $150 million, potentially reaching $353 million with warrant exercises.
The funds will support ongoing Phase 3 trials (COMP005 and COMP006) for treatment-resistant depression (search), with data expected in 2025 and 2026.
A portion of the proceeds will also accelerate a late-stage development program focused on addressing post-traumatic stress disorder (PTSD (search)).
Compass Pathways plc (Nasdaq: CMPS) has announced the pricing of an underwritten offering aimed at raising capital to further its research and development efforts in mental health treatments. The offering, which includes American Depositary Shares (ADSs) and pre-funded warrants, is expected to generate gross proceeds of approximately $150 million, potentially increasing to $353 million if ADS warrants are fully exercised.
The offering comprises 24,014,728 ADSs and pre-funded warrants to purchase up to 11,044,720 ADSs. Each ADS and pre-funded warrant is accompanied by an ADS warrant to purchase one ADS at an exercise price of $5.796, a 40% premium to the last sale price, exercisable following a specified data milestone. The offering is priced at $4.275 per ADS and accompanying ADS Warrant, and $4.2649 per pre-funded warrant and accompanying ADS Warrant. The offering is expected to close around January 13, 2025, pending standard closing conditions.
Funding Clinical Trials and Development Programs
Compass Pathways intends to allocate the net proceeds from this offering, along with existing cash reserves, to fund its ongoing COMP005 and COMP006 Phase 3 trials. These trials are evaluating treatments for treatment-resistant depression (search), with data readouts expected in the second quarter of 2025 and the second half of 2026, respectively. Additionally, the company plans to use a portion of the funds to accelerate a late-stage development program targeting post-traumatic stress disorder (PTSD (search)).
The financing round was led by Deep Track Capital, with participation from both new and existing investors. TD Cowen, Cantor, Stifel, and RBC Capital Markets served as joint book-running managers for the offering.
COMP360 and Mental Health Innovation
Compass Pathways is focused on developing evidence-based innovations in mental health, particularly for individuals who do not respond adequately to existing treatments. Their lead investigational drug product, COMP360, is a proprietary formulation of synthetic psilocybin administered in conjunction with psychological support. COMP360 has received Breakthrough Therapy designation from the FDA and ILAP designation in the UK for treatment-resistant depression (search) (TRD).
About Compass Pathways
Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are living with mental health challenges and who are not helped by existing standards of care. We are pioneering the development of a new model of psilocybin treatment, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has Breakthrough Therapy designation from the US Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression (search) (TRD).